Search Results

Signals Research Suite unifies and structures data to be AI-ready. Our automation allows AI and machine-learning tools analyze data so that scientists can focus on innovation.

Modern drug discovery and biosimilar development projects generate very large volumes of data, yet results held in proprietary, legacy and device-dependent unstructured formats can limit access and lead to increased costs and lengthened delays. Help is at hand, with new AI solutions able to find, process, and summarize data from almost any source in near...

This article discusses how digital transformation is enhancing R&D efficiency in the pharmaceutical and chemical industries.

This article discusses the role of digital tools like the Signals Research Suite in optimizing biosimilar development by streamlining data capture, analysis, and collaboration.

This article highlights the role of data strategies in accelerating the development of new drug modalities

This article highlights the critical role of an AI-ready data strategy in drug discovery, emphasizing that AI is only as effective as the quality of data it processes.

This article explores how AI and ML are revolutionizing drug discovery by enhancing data accessibility, automating chemical reaction recommendations, and improving cellular imaging.